<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00593502</url>
  </required_header>
  <id_info>
    <org_study_id>MV21118</org_study_id>
    <secondary_id>EudraCT 2007-004734-17</secondary_id>
    <nct_id>NCT00593502</nct_id>
  </id_info>
  <brief_title>Early Oseltamivir Treatment of Influenza in Children 1-3 Years of Age</brief_title>
  <acronym>ETOPOM</acronym>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled Study of Early Oseltamivir Treatment of Influenza in Children 1-3 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital District of Southwestern Finland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital District of Southwestern Finland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to assess the efficacy of early oseltamivir treatment
      (started within 24 hours of the onset of influenza symptoms) in preventing the development of
      acute otitis media as a complication of influenza in children aged 1-3 years.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of influenza-infected children in whom acute otitis media develops after the start of study medication</measure>
    <time_frame>1-8 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to resolution of fever and other clinical symptoms</measure>
    <time_frame>1-21 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">409</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oseltamivir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oseltamivir</intervention_name>
    <description>Body weight: ≤ 15 kg, 30 mg twice daily; 15 - ≤ 23 kg, 45 mg twice daily; 23 - ≤ 40 kg, 60 mg twice daily; &gt; 40 kg, 75 mg twice daily, for 5 days</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Tamiflu</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>The dosage of placebo will be similar to the active drug</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 1-3 years

          -  Fever = or &gt; 38.0 C and at least one respiratory symptom OR fever = or &gt; 38.0 C and a
             positive influenza rapid test

        Exclusion Criteria:

          -  Confirmed infection with any other respiratory virus than influenza.

          -  Suspicion of invasive bacterial infection requiring immediate admission to hospital

          -  Evidence of a poorly controlled underlying medical condition

          -  Known immunosuppression (malignancy, transplant, drugs)

          -  Known allergy to oseltamivir or paracetamol

          -  Received oseltamivir within 4 weeks

          -  Participation in another clinical trial with an investigational drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>3 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Terho J Heikkinen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Turku University Hospital, Turku, Finland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <reference>
    <citation>Heikkinen T, Silvennoinen H, Peltola V, Ziegler T, Vainionpaa R, Vuorinen T, Kainulainen L, Puhakka T, Jartti T, Toikka P, Lehtinen P, Routi T, Juven T. Burden of influenza in children in the community. J Infect Dis. 2004 Oct 15;190(8):1369-73. Epub 2004 Sep 15.</citation>
    <PMID>15378427</PMID>
  </reference>
  <reference>
    <citation>Whitley RJ, Hayden FG, Reisinger KS, Young N, Dutkowski R, Ipe D, Mills RG, Ward P. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J. 2001 Feb;20(2):127-33. Erratum in: Pediatr Infect Dis J 2001 Apr;20(4):421.</citation>
    <PMID>11224828</PMID>
  </reference>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2008</study_first_submitted>
  <study_first_submitted_qc>January 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2008</study_first_posted>
  <last_update_submitted>June 18, 2009</last_update_submitted>
  <last_update_submitted_qc>June 18, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2009</last_update_posted>
  <responsible_party>
    <name_title>Terho Heikkinen/Consulting Pediatrician, Assistant Professor</name_title>
    <organization>Turku University Hospital, Turku, Finland</organization>
  </responsible_party>
  <keyword>influenza</keyword>
  <keyword>children</keyword>
  <keyword>acute otitis media</keyword>
  <keyword>oseltamivir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oseltamivir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

